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Abstract
Background In relation to the extensive use of herbal
medicinal products in self-care, the safety information is
limited and there is a need for improvement. This study
describes spontaneously reported adverse reactions related to
herbal medicinal products and natural remedies in Sweden.
Objectives To evaluate the characteristics and frequency
of adverse events recorded by the Swedish Medical Prod-
ucts Agency, where herbal medicinal products and natural
remedies were suspected as causative agents.
Methods Adverse drug reactions reported to the Swedish
Medical Product Agency during 2007–15 related to
approved herbal medicinal products or natural remedies
were included and analysed in the retrospective study.
Reports had been assessed for causality when they were
lodged and only reports that had been assessed as at least
possible were included in the study.
Results In total, 116 reports (concerning 259 adverse
reactions) related to herbal medicinal products or natural
remedies were found in the Swedish national pharma-
covigilance database. The active ingredients most fre-
quently suspected during the study period were black
cohosh rhizome (15 reports), purple coneflower herb (14
reports) and a combination of extracts of pollen (13
reports). Adverse reactions related to skin and subcuta-
neous tissue were the most commonly reported reactions.
Conclusions No previously unknown safety problems have
been discovered in the present study. This finding could be
explained by a thorough pre-approval assessment of
medicinal products and the fact that most herbal prepara-
tions in medicinal products have been in clinical use for
many years (for traditional herbal medicinal products, the
requirements are C30 years), i.e. adverse reactions are
acknowledged and assessed before approval.
Key Points
The most commonly reported adverse reactions for
herbal medicinal products and natural remedies were
related to skin and subcutaneous tissue. These
reactions could be the result of hypersensitivity and
can be viewed as an inherent problem with herbal
treatments.
In relation to the extensive use of herbal medicinal
products in self-care, the safety information is
limited. Healthcare professionals and patients are
encouraged to discuss the use of and report suspected
adverse reactions related to herbal medicinal
products.
1 Introduction
Medicinal products included in the study, with the active
ingredient of herbal origin, are approved according to the
current European Directive 2001/83/EC. These products
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can be approved as herbal medicinal products (HMPs) or as
traditional herbal medicinal products (THMPs). In Sweden,
there is also a national law allowing approved natural
remedies (NRs) with active ingredients of natural origin
that are of non-herbal origin, i.e. consists of an animal part,
a bacterial culture, a mineral or a salt [1]. Natural remedies
are always intended for self-care. All three categories,
HMPs, THMPs and NRs, have the same requirements
regarding the quality of the product as any other medicinal
product. The main distinction between HMPs and THMPs
is that the efficacy requirements for THMPs consist solely
of long-standing medicinal use (15 years within the Euro-
pean Economic Area and 30 years worldwide). In addition,
THMPs are strictly limited to self-medication that does not
require a physician’s diagnosis, prescription or supervision
of treatment. The THMPs are only intended for oral
administration, external application and/or inhalation. A
recent publication provides the details of the requirements
for HMPs and THMPs in the European Union [2].
In relation to the widespread use of HMPs, THMPs and
NRs in self-care, the safety information from actual use is
limited and there is a constant demand for increasing
adverse drug reaction (ADR) reporting. We believe that
analysing pharmacovigilance data, i.e. ADR reports, is one
approach to increase the awareness in this important area.
Therefore, in the present study we investigated the pattern
of ADRs related to approved medicinal products of natural
origin (HMPs, THMPs and NRs) in Sweden.
Our study is a follow-up on the study by Jacobsson
et al., which investigated the pattern of spontaneously
reported adverse reactions related to complementary and
alternative medicinal (CAM) products in Sweden over two
decades, between 1987 and 2006 [3]. Our study followed
all spontaneously reported ADRs of HMPs in Sweden over
almost another decade, between 1 January, 2007 and 31
December, 2015. During this period, the average number of
HMPs, THMPs and NRs in Sweden each year was
approximately 100 products, mainly over-the-counter
products and they account for approximately 10% of the
over-the-counter products on the Swedish market.
There is one important difference between the present
study and the previous study. The previous study by
Jacobsson et al. [3] included CAM products in a broader
sense, i.e. reports of adverse reactions related to food
supplements were also included. During the time period of
that study, reports related to food supplements were regu-
larly sent to the Swedish Medical Products Agency (MPA)
and included in the Swedish pharmacovigilance database.
However, food supplements do not fall under the phar-
macovigilance legislation and adverse reactions related to
the intake of food supplements should now be reported to
the National Food Agency in Sweden. For the last few
years, reports related to food supplements have not been
available in the MPA pharmacovigilance database and are
not included in this study. Hence, the MPA can only
monitor the safety of approved medicinal products.
Therefore, the aim of this report is to evaluate the char-
acteristics and frequency of adverse events recorded by the
MPA, where HMPs, THMPs and NRs were suspected as
causative agents.
2 Methods
All spontaneously reported ADRs to the Swedish MPA
between 1 January, 2007 and 31 December, 2015, where at
least one medicinal product was categorised as a HMP, a
THMP or as a NR that was suspected to cause the ADR,
were included in this retrospective study.
Each assessed ADR report contains information about
the patient, the ADR, and the treatment suspected to have
caused it and concomitant drugs. Concomitant drugs pre-
sented in this study include both suspected and non-sus-
pected drugs. No causality assessment is presented for
concomitant drugs.
A report can contain one or more ADRs connected to
one or more treatments. This information, as well as the
MPA’s causality assessment, are stored in the Swedish
national pharmacovigilance database. All ADRs reported
to the MPA are evaluated and a causality assessment is
added to the report. The causality assessment is made
according to the World Health Organization’s criteria
(Supplementary Table 1). Only reports rated possible or
higher were included in the study.
The reported adverse reactions are presented according
to the MedDRA (Medical Dictionary for Regulatory
Activities) classification. The MedDRA classification is
divided into five levels of hierarchy ranging from a very
specific term, i.e. how it might be written in the report, to a
system organ class. The adverse reactions in Supplemen-
tary Tables 2–5 are presented with the preferred term level,
which is a single medical concept for a symptom (http://
www.meddra.org/how-to-use/basics/hierarchy).
The type of report is also categorised as serious or non-
serious. The definition of a serious adverse reaction is an
adverse reaction that results in death, is life-threatening,
requires inpatient hospitalisation or prolongation of exist-
ing hospitalisation, results in persistent or significant dis-
ability or incapacity, or is a congenital anomaly/birth
defect (Directive 2001/83/EC). The reporter may also set
the case as other serious medical event. The remaining
reports are considered non-serious. Every serious ADR
report is assessed by a physician at the MPA.
From each included report, the suspected herbal prepa-
ration, the adverse reaction/s, the severity of the adverse
reaction (i.e. serious/non-serious) and the source of the
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report are recorded. In this study, the source of the report is
characterised as a healthcare professional (physician,
nurse, pharmacist or dentist) or patient report. Reports from
marketing authorisation (registration) holders are not
included in the Swedish national pharmacovigilance data-
base. Thus, duplicate reports do not occur.
3 Results
A total of 116 reports with 259 adverse reactions
reported to be related to HMPs, THMPs or NRs were
identified in the Swedish pharmacovigilance database
during the study period. The numbers of reports per year
during 2007–15 are shown in Fig. 1. The total number of
reports per year varies between six and 21 reports. In
addition, the number of reports per year from healthcare
professionals and patients are presented in Fig. 1. The
vast majority of reports (113/116) included in the study
had been causality assessed as ‘possible’. Three reports
(3/116) were assessed as ‘probable’. These three were
non-serious reports from healthcare professionals. For
each year since patient reporting was started, the MPA
has received patient reports related to HMPs, THMPs, or
NRs.
The total numbers of reports assessed as serious and
non-serious from patients and healthcare professionals
during the study period are shown in Table 1. The most
frequently suspected active substances and number of
reports during the study period are also presented in
Table 1. All other active substances had seven or fewer
reports. For detailed data, all individual serious reports
from healthcare professionals and patients are presented in
Supplementary Tables 2 and 3, respectively. The individ-
ual non-serious reports from healthcare professionals and
patients are presented in Supplementary Tables 4 and 5,
respectively.
The interpretation of serious reactions was hampered by
the fact that many of the reports contained concomitant
medications or had low narrative quality (in the latter case,
mainly patient reports). In an attempt to describe a typical
serious reaction concerning the most frequently occurring
plant materials, we summarise below three (A–C) of the
healthcare reports related to the most frequently suspected
herbal materials and with no concomitant medications
mentioned.
A.A middle-aged woman experienced a pricking sen-
sation in her throat, lips and tongue, approximately 2–3 h
after intake of a lozenge containing purple coneflower.
Fig. 1 Total number of reports per year for herbal medicinal
products, traditional herbal medicinal products and natural remedies
(filled triangles), number of reports per year from healthcare
professionals (filled diamonds) and number of reports per year from
patients (filled squares)
Table 1 Serious and non-serious reports between 2007 and 2015 and the most frequently suspected active substances
Total number of reports assessed as serious and non-serious between 2007 and 2015
Source of the report Number of serious reports Number of non-serious reports Total number of reports
Healthcare professional 21 40 61
Patient 13 42 55
Most frequently suspected active substances between 2007 and 2015 (total number of reports, n = 116)






Black cohosh rhizome (Cimicifuga racemosa L. Nutt.) 5 10 15
Purple coneflower herb, expressed juice
(Echinacea purpurea (L.) Moench)
3 11 14
Pollen of maize, rye, cock’s-foot, pine (Zea mays
L., Secale cereal L., Dactylis glomerata L., Pinus sylvestris L.)
4 9 13
Gentian root, primula spp. flowers, sorrel spp. herb, elder flower,
verbena herb (Gentiana lutea L., Primula spp., Rumex
spp., Sambucus nigra L., Verbena officinalis L.)
7 5 12
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Examination revealed redness on the throat. She was
treated with corticosteroids and antihistamines. The con-
dition gradually improved and the patient was discharged
from hospital later the same day.
B.A previously healthy middle-aged woman presented
at the emergency room with pain in the epigastrium,
radiating to the right flank, and nausea. Her liver
enzymes were considerably increased and continued to
rise on her second day at the hospital and started to
improve on the third day. She had begun self-medication
with an HMP containing pollen of maize, rye, cock’s
foot and pine, approximately 2 weeks prior to the
emergency room visit. Her medication was stopped and
at follow-up 3 weeks later, her liver enzymes were
almost normalised. The normalisation of the liver
enzymes was interpreted as a positive de-challenge
(Supplementary Table 1). Infection parameters were
normal and there were no evidence for an autoimmune
hepatitis. The reported diagnosis was a mixed liver
reaction associated with the HMP.
C.A woman was experiencing a cold. After 1 day’s use
of an HMP containing gentian root, primula spp. flowers,
sorrel spp. herb, elder flower and verbena herb, she
developed a generalised urticaria. She self-medicated with
antihistamines and went to sleep. The following morning
she woke with swollen lips and face and a tingling sensa-
tion in one cheek. At the emergency room, she was treated
with corticosteroids and antihistamines. A diagnosis of
erythema multiforme was made. She recovered slowly and
was discharged after a few days.
In Table 2, the most frequently reported adverse reac-
tions are presented according to the MedDRA classification
at the system organ class level. Similar to the previous
publication [3], adverse reactions related to the skin and
subcutaneous tissue were the most commonly reported
reactions (Table 2).
4 Discussion
The main finding was that no previously unknown safety
problems related to the use of HMPs have been discovered.
Importantly, this conclusion is based upon high-quality
data. All reports in the present study were assessed for
causality and only reports rated as at least possible were
included in the study. It takes fewer high-quality reports to
form a basis for a signal and to understand the clinical
relevance of the signal. Moreover, the regulatory system
for medical products with a thorough assessment of the
quality of the ingredients allows us to know with certainty
which plant species and plant parts were implicated in the
ADR. This is not always the case with herbal treatments,
for example, in a systematic review of paediatric herbal
adverse events from Gardiner et al., the implicated plant
part was known only in 41% of the cases [4]. In the present
study, the plant part is known in 100% of the cases.
In the present study, ADRs related to the skin and
subcutaneous tissue are the most commonly reported
reactions. This finding is in agreement with a previous
study by Jacobsson et al. [3] and also in agreement with
data from the World Health Organization [5]. Adverse skin
and subcutaneous tissue reactions could be the result of
hypersensitivity, including allergy, and can be viewed as an
inherent problem with herbal treatments. Regulatory
actions include appropriate labelling for medicinal prod-
ucts to minimise risks. A known hypersensitivity to the
ingredients of an HMP is always a contraindication for use.
This information is conveyed in the summary of product
characteristics to healthcare professionals and to the patient
in the product information leaflet. Unfortunately, not all
patients are aware of their allergies or the possibility of
cross-reactivity. Therefore, spontaneously reported ADRs
related to hypersensitivity and allergies are expected to
continue in a similar extent.
Table 2 Most frequently reported ADRs by SOC
SOC Number of
reportsa
Suspected active substances with three or more ADRs (number of ADRs)
Skin and subcutaneous
tissue disorders
32 Purple coneflower herb, expressed juice (7), gentian root, primula spp. flowers, sorrel spp. herb,
elder flower, verbena herb (6), black cohosh rhizome (4), valerian root (3), St John’s wort (3)
Gastrointestinal disorders 29 Gentian root, primula spp. flowers, sorrel spp. herb, elder flower, verbena herb (4), thyme herb and
marshmallow root (4), valerian root (3)
Investigations 23 Black cohosh rhizome (7), Purple coneflower herb, expressed juice (3), pollen of maize, rye,
cock’s-foot, pine (3), valerian root (3)
General disorders 21 Valerian root (4), pollen of maize, rye, cock’s-foot, pine (3), purple coneflower herb, expressed
juice (3), black cohosh rhizome (3)
Nervous system disorders 20 Horse-chestnut seed (3), Arctic root root (3), pollen of maize, rye, cock’s-foot, pine (3), St John’s
wort (3)
ADRs adverse drug reactions, SOC system organ class
a One report can contain one or more ADRs
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In the study by Jacobsson et al. [3], 35 cases of CAM-
drug interaction causality assessed as ‘possible’ were
reported. The most frequent interactions during this study
period involved St John’s wort. The interaction potential of
St John’s wort was observed and assessed by the Swedish
MPA in the late 1990s. Today, the knowledge of the
interaction potential of St John’s wort is widespread among
healthcare professionals and carefully communicated to
patients in the product information leaflet. In the present
study, there are no reports related to drug interactions and
the use of St John’s wort and only two reports related to
drug interactions and the use of HMPs. These two reports
on drug interaction concern the use of saw palmetto and an
anticoagulant, dabigatran and warfarin, respectively. The
dramatically reduced number of case reports on St John’s
wort interactions with other medicinal products could be
explained by the increased awareness of the problem,
which highlights the impact and importance of efficiently
communicating safety signals.
Liver toxicity has been associated with the use of black
cohosh, as discussed in the assessment report pertinent to
the European Community herbal monograph on Cimicifuga
racemosa (L.) Nutt., rhizoma [6, 7], where it is concluded
that the available non-clinical and clinical data on liver
toxicity associated with black cohosh are limited but the
risk cannot be excluded and it is suggested that further case
reports should be assessed thoroughly using the Roussel
Uclaf Causality Assessment Method [8] to collect high-
quality data. Jacobsson et al. discuss in their study from
2008 [3] that several reports of different adverse liver
reactions in subjects using black cohosh have been
received by authorities in several countries, including six
reports from Sweden (i.e. three reports on elevated
transaminases and three reports on other various hepatic
reactions). In the present retrospective study, five serious
reports concerning black cohosh related to the liver. One
report is from a patient (no laboratory values), the
remaining four hospital reports unfortunately do not con-
tain sufficient information for a Roussel Uclaf Causality
Assessment Method-based analysis. The reports have been
causality assessed only as possible and are confounded by
co-medications. The absence of a Roussel Uclaf Causality
Assessment Method and cofounding co-medications pre-
vents any conclusion on liver toxicity associated with black
cohosh in this study.
The number of spontaneously reported adverse reactions
in this study is on average 13 reports per year. This number
is much lower than the annual number of reports in the
previous study by Jacobsson et al. [3], which reported an
average of 39 reports annually. Interestingly, this outcome
could be owing to the lack of reports related to non-
medicinal product (e.g. food supplements) in the present
study. Unfortunately, the number of reports related to non-
medicinal products in the Jacobsson et al. study is
unknown, and a direct comparison is therefore not possible.
It may be that either the majority of reports in the Jacob-
sson et al. [3] study concerned non-medicinal products, or
that healthcare reporting for HMPs, THMPs and NRs has
decreased during the period of the present study.
Besides the differences of included products, another
important difference compared with the study by Jacob-
sson et al. [3] is the definition of an adverse reaction. In
July 2012, a new European pharmacovigilance legislation
came into effect [9]. Since then, the definition of an
adverse reaction was changed to include not only a
response to a medicinal product, which is noxious and
unintended at normal doses, but also from medication
errors and uses outside the terms of the marketing
authorisation (off-label use), including misuse and abuse
of the medicinal product.
The last important difference between the present study
and the previous one stems from the fact that in addition to
reporting by healthcare professionals, pharmacists and
patients may also report adverse reactions. These novel
reporting routes have been implemented in Sweden since
the previous study by Jacobsson et al. [3] and the impact of
patient reporting of ADRs related to HMPs is discussed
later in this report.
Comparisons between the previous and the present
publication could very roughly be viewed as a comparison
between the safety profile of all CAM products (previous
study) and medicinal products, which have been assessed
with respect to quality, safety and efficacy before they are
placed on the market, i.e. medicinal products (present
study). In contrast to the previous publication, which
reported five fatalities, where the causality between the
ADRs and the CAM substance was assessed as at least
possible, the present study using the same causality cri-
teria contains no fatal adverse reactions. This finding is
not surprising because herbal preparations in (T)HMPs
have been in clinical use for many years before the
approval of the products, allowing time for ADRs to be
acknowledged and assessed. In addition, post-approval
monitoring of approved medicinal products reduces the
risk that self-care products with severe safety problems
remain on the market.
For all medicinal products, underreporting of ADRs is
still the major issue in spontaneous reporting, and under-
reporting could be an alternative explanation for the lack of
reports regarding fatalities. It is estimated that only 6% of
all ADRs are reported [10]. Contributing factors for the
underreporting of ADRs in the present study may be owing
to the misbelief that substances derived from nature are
generally safe. We also suspect that the use of herbal self-
care products is not always being communicated by
patients to their healthcare professionals. For example, in a
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recent study from Germany concerning elderly patients,
only six out of ten patients informed their general practi-
tioner of their CAM use [11]. A similar estimation was
made in an American study, where more than half of the
participants did not disclose their use of herbal treatments
to the healthcare professionals [12].
Today, safety of herbal preparations included in
medicinal products is also assessed and harmonised on a
European level. After the establishment of a pan European
legislation [13], approximately 140 European Union herbal
monographs have been published by the European Com-
mittee on HMPCs on the European Medicines Agency
website (www.ema.europa.eu). In these monographs, the
member states have assessed and agreed upon important
safety and efficacy information on herbal preparations. The
monographs, and other safety information published by the
HMPC, facilitate and harmonise the processes of approval
and the registration of HMPs in the European Union. The
committee has continuously published public statements
regarding toxic substances found in herbal treatments, for
example, pyrrolizidine alkaloids, thujone and aristolochic
acid.
As an example that non-medicinal products can pose a
threat to the consumer, a product based on shark liver oil
led to nine reports of pulmonary embolism, which became
one of the most common serious adverse reactions in the
previous publication by Jacobsson et al. [3]. No medicinal
products based on shark liver oil are approved in Sweden
today, and no cases of pulmonary embolism were reported
in the present study.
Many initiatives have been developed with the aim of
improving healthcare reporting, such as educational activ-
ities, means of assisting the reporter and electronic sub-
mission of ADRs. One of the investigated initiatives is
feedback to the reporter [10]. We believe that publication
of assessed data from national competent authorities is one
way to convey positive feedback and inspire reporting. It is
our hope that the present study will be a reminder to
healthcare professionals to discuss self-care products with
patients, and to bear in mind that also HMPs, THMPs and
NRs can cause ADRs.
5 Conclusions
This report from the MPA aims to investigate, summarise
and discuss ADR reports related to HMPs, THMPs, and
NRs on the Swedish market. In agreement with other
studies in the field, adverse reactions related to the skin and
subcutaneous tissue were the most commonly reported
reactions. Importantly, no previously unknown safety
problems were discovered. Adverse drug reaction reports
from patients and healthcare professionals are a powerful
tool to ensure the safe use of HMPs post-approval, and
healthcare professionals and patients are therefore
encouraged to report suspected adverse reactions related to
HMPs.
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